Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026.  The patent is expected to be granted shortly after August 28, 2026.

The Australian notice of allowance further strengthens Marvel's global composition-of-matter patent portfolio for MB-204, reinforcing the Company's intellectual property position as it advances into Phase I clinical development following positive preclinical efficacy and toxicology results. Such includes recent preclinical studies in Rett syndrome models that demonstrated that MB-204 significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints and produced sustained therapeutic benefits that persisted after treatment cessation, suggesting the potential for disease-modifying effects. Broadening patent protection across key pharmaceutical markets enhances the asset's commercial value by extending market exclusivity, reducing competitive risk, and increasing its attractiveness for potential licensing, partnering, and strategic investment opportunities.

“We are continuing to extend our composition of matter patent protection of MB-204 to all major markets”, commented Marvel CEO Rod Matheson “and we continue to look forward to receiving similar rulings for the other jurisdictions. We have also recently filed for patents on a novel liquid-based formulation of MB-204 which should help lengthen the lifetime of our patent estate.”

MB-204 is a novel fluorinated analogue of the approved adenosine A2a receptor antagonist Istradefylline which is used for the treatment of Parkinson’s Disease. MB-204 has demonstrated superior pharmacokinetics and completed pre-clinical toxicology testing and has shown excellent pre-clinical efficacy studies in depression and multiple models of autism including Rett Syndrome. The compound is currently being tested in Fragile X models. Currently, around 1 in 36 children at age 8 have been diagnosed with autism spectrum disorder which underscores the urgency for new agents.

Schreibe Deinen Kommentar